FRI, SEP 1ST, 2023, 13:00 CET

ChloraSolv recommended for UK CA certification required for UK market after Brexit

As a result of Brexit, a so-called UK CA certification will be required for medical devices placed on the market in Great Britain. Today, a positive recommendation for UK CA certification has been provided for RLS Global’s wound debridement product ChloraSolv.

“RLS Global has now secured a long-term regulatory compliance, and hence, access to the UK market for ChloraSolv”, says Roland Frösing, acting CEO, RLS Global.

RLS Global is now awaiting the formal UK CA certificate.


THIS IS CHLORASOLV
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.1 ChloraSolv does not damage healthy tissue and is well tolerated by the patient.

  1. Eliasson, B., Fagerdahl, A.M., Jönsson, A., Apelqvist, J. Debriding effect of amino acid-buffered hypochlorite on hard-to-heal wounds covered by devitalized tissue: pilot study. Journal of Wound Care (June 2021) 30(6):455–464.

 

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

FOR MORE INFORMATION, PLEASE CONTACT:
Roland Frösing, acting CEO, RLS Global
Telefon: +46 723 20 61 00
E-post: roland.frosing@rlsglobal.se